Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Featuring perspectives from Prof John Seymour, including the following topics:

Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)

CME information and select publications